-       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - February 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - November 2025
    -  489 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  368 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                  -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                   -       Report 
   - December 2024
    -  61 Pages 
    Global
   
   From       €2840EUR$3,160USD£2,491GBP 
      €3550EUR$3,950USD£3,114GBP 
                -       Report 
   - May 2025
    -  114 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                  -       Report 
   - May 2025
    -  150 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - August 2025
    -  150 Pages 
    Global
   
   From       €3018EUR$3,358USD£2,647GBP 
      €3550EUR$3,950USD£3,114GBP 
                -       Report 
   - December 2024
    -  108 Pages 
    Global
   
   From       €13478EUR$14,995USD£11,820GBP 
                -       Report 
   - July 2023
    -  180 Pages 
    Global
   
   From       €5348EUR$5,950USD£4,690GBP 
                  -       Report 
   - May 2024
    -  132 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                -       Report 
   - January 2023
    -  470 Pages 
    Global
   
   From       €4494EUR$5,000USD£3,941GBP 
                -       Report 
   - March 2024
    -  200 Pages 
    Global
   
   From       €3730EUR$4,150USD£3,271GBP 
                -       Report 
   - January 2024
    -  200 Pages 
    Global
   
   From       €3730EUR$4,150USD£3,271GBP 
                -       Report 
   - October 2023
    -  145 Pages 
    Global
   
   From       €2831EUR$3,150USD£2,483GBP 
                  -       Drug Pipelines 
   - July 2024
    -  150 Pages 
    Global
   
   From       €2696EUR$3,000USD£2,365GBP 
      €3371EUR$3,750USD£2,956GBP 
                  -       Report 
   - April 2023
    -  180 Pages 
    Global
   
   From       €2337EUR$2,600USD£2,049GBP 
      €2921EUR$3,250USD£2,562GBP 
                -       Report 
   - April 2023
    -  117 Pages 
    North America
   
   From       €4269EUR$4,750USD£3,744GBP 
             
         The Glaucoma Drug market is a subset of the Optical Disorders Drugs market, which includes medications used to treat a variety of eye conditions. Glaucoma is a group of eye diseases that cause damage to the optic nerve, resulting in vision loss. Glaucoma drugs are used to reduce intraocular pressure, which is the main risk factor for glaucoma. These drugs can be administered orally, topically, or through injections. Commonly used glaucoma drugs include prostaglandin analogs, beta blockers, alpha    agonists, carbonic anhydrase inhibitors, and cholinergic agonists.
Some of the major companies in the Glaucoma Drug market include Allergan, Pfizer, Merck, Novartis, Bausch Health, Sun Pharmaceuticals, Santen Pharmaceuticals, and Alcon. Show Less   Read more